Tag Archives: diabetes biomarkers

A1C is one of the most useful tools in diabetes care, but it has an important limitation: it takes time to reflect change. Could a faster-moving marker help clinicians know sooner whether treatment is working? New randomized research on glycated albumin in diabetes offers an intriguing answer. Glycated albumin reflects …

Could a stool sample someday help clinicians choose a diabetes medication before writing the prescription? Emerging research into gut biomarkers in diabetes is moving that possibility closer to clinical reality. Rather than simply cataloging which bacteria live in the intestine, researchers are examining microbial genes, stool-derived metabolites, and functional signatures …

Diabetes research is moving beyond blood sugar measurements and insulin therapy into an exciting new frontier. One of the most promising areas involves microRNAs, tiny RNA molecules that quietly regulate hundreds of genes throughout the body. Although they are microscopic, their influence on insulin production, inflammation, and blood vessel health …

Early detection has always been one of the biggest challenges in diabetes care. What if doctors could identify patients at high risk for diabetic neuropathy or kidney disease years before symptoms developed? That possibility is driving exciting new research into IgG glycosylation in diabetes, an emerging area that examines subtle …

Diabetes often develops silently for years before blood sugar levels become high enough for a diagnosis. What if tiny biological packages circulating in the bloodstream could reveal those hidden changes long before symptoms appear? Researchers are increasingly studying how exosomes may serve as biomarkers for diabetes because these microscopic messengers …

Diabetes is often diagnosed only after blood sugar levels have already risen above normal. However, what if the earliest warning signs appeared years before glucose levels changed? That question is driving exciting research into metabolomics, a rapidly growing field that analyzes tiny molecules produced during normal metabolism. Instead of focusing …

For many years, C-peptide testing was viewed as a simple tool to distinguish type 1 diabetes from type 2 diabetes. However, the story has changed. As researchers gain a better understanding of pancreatic beta-cell function, C-peptide testing in diabetes has become much more valuable than a diagnostic aid alone. Today, …

For decades, A1C has served as the gold standard for assessing long-term glucose control in people with diabetes. However, it tells only part of the story. Researchers are now exploring whether metabolic flexibility could become an important biomarker in diabetes, offering a deeper understanding of metabolic health than A1C alone. …

Population-based screening for type 1 diabetes is entering a new era. While autoantibody testing remains the gold standard for identifying individuals at high risk, researchers are increasingly investigating whether type 1 diabetes genetic screening could identify susceptible people even earlier. Advances in genomic science now make it possible to estimate …

As population-based screening for type 1 diabetes (T1D) becomes more common, clinicians increasingly encounter positive islet autoantibody results in children and adults who have no symptoms. However, not all positive screening results carry the same clinical significance. A single positive autoantibody may indicate elevated risk, yet the specific antibody detected …